Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy
Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in E...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Rajan, Shiv [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Association of Gynecologic Oncologists of India 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Gynecologic Oncology - New Delhi : Springer India, 2015, 19(2021), 4 vom: 16. Aug. |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2021 ; number:4 ; day:16 ; month:08 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40944-021-00575-z |
|---|
| Katalog-ID: |
SPR044847440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044847440 | ||
| 003 | DE-627 | ||
| 005 | 20230509095930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210817s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40944-021-00575-z |2 doi | |
| 035 | |a (DE-627)SPR044847440 | ||
| 035 | |a (SPR)s40944-021-00575-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rajan, Shiv |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Association of Gynecologic Oncologists of India 2021 | ||
| 520 | |a Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. | ||
| 650 | 4 | |a Response assessment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a RECIST 1.1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ovarian cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neoadjuvant chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytoreduction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interval debulking surgery |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Akhtar, Naseem |4 aut | |
| 700 | 1 | |a Sharma, Sonali |4 aut | |
| 700 | 1 | |a Gupta, Sameer |4 aut | |
| 700 | 1 | |a Kumar, Vijay |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Gynecologic Oncology |d New Delhi : Springer India, 2015 |g 19(2021), 4 vom: 16. Aug. |w (DE-627)827030576 |w (DE-600)2823586-1 |x 2363-8400 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:4 |g day:16 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40944-021-00575-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 4 |b 16 |c 08 | ||
| author_variant |
s r sr n a na s s ss s g sg v k vk |
|---|---|
| matchkey_str |
article:23638400:2021----::rdcigopeeyoeutoioainacrainsyeit1rtraolw |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s40944-021-00575-z doi (DE-627)SPR044847440 (SPR)s40944-021-00575-z-e DE-627 ger DE-627 rakwb eng Rajan, Shiv verfasserin aut Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Gynecologic Oncologists of India 2021 Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 Akhtar, Naseem aut Sharma, Sonali aut Gupta, Sameer aut Kumar, Vijay aut Enthalten in Indian Journal of Gynecologic Oncology New Delhi : Springer India, 2015 19(2021), 4 vom: 16. Aug. (DE-627)827030576 (DE-600)2823586-1 2363-8400 nnns volume:19 year:2021 number:4 day:16 month:08 https://dx.doi.org/10.1007/s40944-021-00575-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2021 4 16 08 |
| spelling |
10.1007/s40944-021-00575-z doi (DE-627)SPR044847440 (SPR)s40944-021-00575-z-e DE-627 ger DE-627 rakwb eng Rajan, Shiv verfasserin aut Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Gynecologic Oncologists of India 2021 Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 Akhtar, Naseem aut Sharma, Sonali aut Gupta, Sameer aut Kumar, Vijay aut Enthalten in Indian Journal of Gynecologic Oncology New Delhi : Springer India, 2015 19(2021), 4 vom: 16. Aug. (DE-627)827030576 (DE-600)2823586-1 2363-8400 nnns volume:19 year:2021 number:4 day:16 month:08 https://dx.doi.org/10.1007/s40944-021-00575-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2021 4 16 08 |
| allfields_unstemmed |
10.1007/s40944-021-00575-z doi (DE-627)SPR044847440 (SPR)s40944-021-00575-z-e DE-627 ger DE-627 rakwb eng Rajan, Shiv verfasserin aut Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Gynecologic Oncologists of India 2021 Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 Akhtar, Naseem aut Sharma, Sonali aut Gupta, Sameer aut Kumar, Vijay aut Enthalten in Indian Journal of Gynecologic Oncology New Delhi : Springer India, 2015 19(2021), 4 vom: 16. Aug. (DE-627)827030576 (DE-600)2823586-1 2363-8400 nnns volume:19 year:2021 number:4 day:16 month:08 https://dx.doi.org/10.1007/s40944-021-00575-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2021 4 16 08 |
| allfieldsGer |
10.1007/s40944-021-00575-z doi (DE-627)SPR044847440 (SPR)s40944-021-00575-z-e DE-627 ger DE-627 rakwb eng Rajan, Shiv verfasserin aut Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Gynecologic Oncologists of India 2021 Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 Akhtar, Naseem aut Sharma, Sonali aut Gupta, Sameer aut Kumar, Vijay aut Enthalten in Indian Journal of Gynecologic Oncology New Delhi : Springer India, 2015 19(2021), 4 vom: 16. Aug. (DE-627)827030576 (DE-600)2823586-1 2363-8400 nnns volume:19 year:2021 number:4 day:16 month:08 https://dx.doi.org/10.1007/s40944-021-00575-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2021 4 16 08 |
| allfieldsSound |
10.1007/s40944-021-00575-z doi (DE-627)SPR044847440 (SPR)s40944-021-00575-z-e DE-627 ger DE-627 rakwb eng Rajan, Shiv verfasserin aut Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Association of Gynecologic Oncologists of India 2021 Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 Akhtar, Naseem aut Sharma, Sonali aut Gupta, Sameer aut Kumar, Vijay aut Enthalten in Indian Journal of Gynecologic Oncology New Delhi : Springer India, 2015 19(2021), 4 vom: 16. Aug. (DE-627)827030576 (DE-600)2823586-1 2363-8400 nnns volume:19 year:2021 number:4 day:16 month:08 https://dx.doi.org/10.1007/s40944-021-00575-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2021 4 16 08 |
| language |
English |
| source |
Enthalten in Indian Journal of Gynecologic Oncology 19(2021), 4 vom: 16. Aug. volume:19 year:2021 number:4 day:16 month:08 |
| sourceStr |
Enthalten in Indian Journal of Gynecologic Oncology 19(2021), 4 vom: 16. Aug. volume:19 year:2021 number:4 day:16 month:08 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Response assessment RECIST 1.1 Ovarian cancer Neoadjuvant chemotherapy Cytoreduction Interval debulking surgery |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Gynecologic Oncology |
| authorswithroles_txt_mv |
Rajan, Shiv @@aut@@ Akhtar, Naseem @@aut@@ Sharma, Sonali @@aut@@ Gupta, Sameer @@aut@@ Kumar, Vijay @@aut@@ |
| publishDateDaySort_date |
2021-08-16T00:00:00Z |
| hierarchy_top_id |
827030576 |
| id |
SPR044847440 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044847440</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509095930.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210817s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40944-021-00575-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044847440</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40944-021-00575-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajan, Shiv</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Association of Gynecologic Oncologists of India 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Response assessment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RECIST 1.1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ovarian cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytoreduction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interval debulking surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akhtar, Naseem</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sharma, Sonali</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Sameer</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Vijay</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Gynecologic Oncology</subfield><subfield code="d">New Delhi : Springer India, 2015</subfield><subfield code="g">19(2021), 4 vom: 16. Aug.</subfield><subfield code="w">(DE-627)827030576</subfield><subfield code="w">(DE-600)2823586-1</subfield><subfield code="x">2363-8400</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:16</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40944-021-00575-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">16</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
| author |
Rajan, Shiv |
| spellingShingle |
Rajan, Shiv misc Response assessment misc RECIST 1.1 misc Ovarian cancer misc Neoadjuvant chemotherapy misc Cytoreduction misc Interval debulking surgery Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| authorStr |
Rajan, Shiv |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)827030576 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2363-8400 |
| topic_title |
Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy Response assessment (dpeaa)DE-He213 RECIST 1.1 (dpeaa)DE-He213 Ovarian cancer (dpeaa)DE-He213 Neoadjuvant chemotherapy (dpeaa)DE-He213 Cytoreduction (dpeaa)DE-He213 Interval debulking surgery (dpeaa)DE-He213 |
| topic |
misc Response assessment misc RECIST 1.1 misc Ovarian cancer misc Neoadjuvant chemotherapy misc Cytoreduction misc Interval debulking surgery |
| topic_unstemmed |
misc Response assessment misc RECIST 1.1 misc Ovarian cancer misc Neoadjuvant chemotherapy misc Cytoreduction misc Interval debulking surgery |
| topic_browse |
misc Response assessment misc RECIST 1.1 misc Ovarian cancer misc Neoadjuvant chemotherapy misc Cytoreduction misc Interval debulking surgery |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Gynecologic Oncology |
| hierarchy_parent_id |
827030576 |
| hierarchy_top_title |
Indian Journal of Gynecologic Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)827030576 (DE-600)2823586-1 |
| title |
Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| ctrlnum |
(DE-627)SPR044847440 (SPR)s40944-021-00575-z-e |
| title_full |
Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| author_sort |
Rajan, Shiv |
| journal |
Indian Journal of Gynecologic Oncology |
| journalStr |
Indian Journal of Gynecologic Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Rajan, Shiv Akhtar, Naseem Sharma, Sonali Gupta, Sameer Kumar, Vijay |
| container_volume |
19 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Rajan, Shiv |
| doi_str_mv |
10.1007/s40944-021-00575-z |
| title_sort |
predicting complete cytoreduction in ovarian cancer patients by recist 1.1 criteria following neoadjuvant chemotherapy |
| title_auth |
Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| abstract |
Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. © Association of Gynecologic Oncologists of India 2021 |
| abstractGer |
Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. © Association of Gynecologic Oncologists of India 2021 |
| abstract_unstemmed |
Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC. © Association of Gynecologic Oncologists of India 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
4 |
| title_short |
Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy |
| url |
https://dx.doi.org/10.1007/s40944-021-00575-z |
| remote_bool |
true |
| author2 |
Akhtar, Naseem Sharma, Sonali Gupta, Sameer Kumar, Vijay |
| author2Str |
Akhtar, Naseem Sharma, Sonali Gupta, Sameer Kumar, Vijay |
| ppnlink |
827030576 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40944-021-00575-z |
| up_date |
2024-07-04T02:33:55.977Z |
| _version_ |
1803614091716067328 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044847440</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509095930.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210817s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40944-021-00575-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044847440</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40944-021-00575-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajan, Shiv</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Association of Gynecologic Oncologists of India 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Complete cytoreduction (CC) is one of the most important prognostic factors for epithelial ovarian cancer (EOC). Response to neoadjuvant chemotherapy (NACT) is potentially important to predict CC as well as counseling the patients. We aimed to study if RECIST 1.1 response predicts CC in EOC following NACT. Materials and Methods This prospective observational study included 59 patients of EOC planned for NACT followed by interval debulking surgery (IDS). Response to NACT was assessed by RECIST 1.1 criteria. The level of cytoreduction during IDS was correlated with the radiological response. A Chi-square test was used for the group comparison. Results Half (50%) of patients had an objective response to NACT. CC was feasible in a total of 35 (62.5%) patients. Both response and cytoreduction levels were independent of clinical parameters. We observed 100% CC rates in CR, 95.8% in PR, 50% in SD and 12.5% in PD categories. RECIST 1.1 response was found significantly (p < 0.01) associated with levels of cytoreduction. The sensitivity, specificity, positive predictive value and negative predictive value of RECIST to predict CC were 77.1%, 95.2%, 96.4% and 71.4%, respectively. Conclusions RECIST 1.1 predicts CC in responders (CR/PR) well. We suggest against denying surgery solely based on RECIST criteria in the SD or PD patients. Given its imprecision in these circumstances, patient characteristics such as performance status, perioperative risk and comorbidities should be taken into account. The role of newer antineoplastic agents, three-dimensional or functional imaging and diagnostic laparoscopy should be explored further for predicting CC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Response assessment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RECIST 1.1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ovarian cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytoreduction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interval debulking surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akhtar, Naseem</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sharma, Sonali</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Sameer</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kumar, Vijay</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Gynecologic Oncology</subfield><subfield code="d">New Delhi : Springer India, 2015</subfield><subfield code="g">19(2021), 4 vom: 16. Aug.</subfield><subfield code="w">(DE-627)827030576</subfield><subfield code="w">(DE-600)2823586-1</subfield><subfield code="x">2363-8400</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:16</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40944-021-00575-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">16</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
| score |
7.402323 |